Welcome to the News You Might Have Missed, a weekly roundup of news items to help you catch up and stay informed.
It was a busy week with lots of news, have a look and see you next week for another update.
Numinus to Begin Trading on the OTC Under Symbol NUMIF
The company is pleased to announce that its ticker symbol on the OTC Pink market in the United States will change to “NUMIF” (previously “LKYSF”) when the market opens on Monday, November 22, 2021.
Wesana Health Clinics Surpass 4,000 Administered Ketamine Treatments
Daniel Carcillo, CEO of Wesana Health commented, “This is a significant achievement for Wesana Clinics. There is an urgent need for innovative and effective treatments to combat the current budding epidemics of suicide, addiction, anxiety, and depression. We continue to believe that Wesana’s clinical network remains at the forefront of mental health advancements while maintaining a strong foundation in traditional psychiatric care.”
HAVN Life Successfully Exports Psilocybin from its Jamaica Facility into Canada
“This partnership is a huge win for us as we look to secure additional supply agreements with Canadian companies, now that the integrity of our supply chain from Jamaica has been demonstrated,” says HAVN Life CEO, Tim Moore. “As the research and drug development work on psilocybin moves forward, HAVN Life continues to position itself as a supply chain leader, able to meet the demand for naturally derived psilocybin,” he adds
Clearmind Medicine to Pursue Dual Listing on Nasdaq
The company announced that its board of directors has decided to pursue a dual listing on the Nasdaq Stock Market. Clearmind intends to file a registration statements with the U.S. Securities and Exchange Commission in the coming months. The Company’s common shares will continue to be traded on the Canadian Stock Exchange.
PsyBio Therapeutics Furthers Intellectual Property Portfolio with Six New Manufacturing Patent Applications
“These patent filings are critical components of PsyBio’s corporate development strategy. Continuing to add intellectual property protection provides us with certainty when developing technology for the exclusive use of our team as we continue to develop proprietary bacterial strains,” stated Michael Spigarelli, MD, PhD, MBA, PsyBio’s Chief Medical Officer. “These additional patent filings are key as PsyBio moves towards the initiation of appropriately approved safety and efficacy clinical trials for our selected compounds within the production and manufacturing arena, for the Company as well as for our investors.”
MindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive Measures
Researchers will use digital measurement devices and software to measure the effects of microdoses of LSD on neuroplasticity markers such as BDNF plasma levels, as well as on various sleep measures, mood, cognitive performance, regulation of emotions, quality of life, and immune system response. The study will be conducted by Dr. Kim Kuypers of Maastricht University, a leading global authority on the use of low dose psychedelics.
Ketamine One Subsidiary IRP Health Opens Two New Veteran-Focused Clinics
The Two Clinics are veteran-focused facilities and multidisciplinary in nature. To date, IRP has successfully performed over 10,000 unique treatments for past or present personnel of the Canadian Armed Forces and the Royal Canadian Mounted Police (“RCMP”), as well as first responders including firefighters, law enforcement officers, paramedics and emergency medical technicians.